0001062993-23-009245.txt : 20230417
0001062993-23-009245.hdr.sgml : 20230417
20230417192409
ACCESSION NUMBER: 0001062993-23-009245
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230413
FILED AS OF DATE: 20230417
DATE AS OF CHANGE: 20230417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KIM DENNIS D
CENTRAL INDEX KEY: 0001456750
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 23825148
MAIL ADDRESS:
STREET 1: C/O EMERALD BIOSCIENCE, INC.
STREET 2: 130 NORTH MARINA DRIVE
CITY: LONG BEACH
STATE: CA
ZIP: 90803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0407
4
2023-04-13
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001456750
KIM DENNIS D
C/O CYMABAY THERAPEUTICS, INC.
7575 GATEWAY BLVD., SUITE 110
NEWARK
CA
94560
0
1
0
0
Chief Medical Officer
0
Common Stock
2023-04-13
4
M
0
7781
4.37
A
27781
D
Common Stock
2023-04-13
4
S
0
7781
8.9809
D
20000
D
Common Stock
2023-04-17
4
M
0
112219
4.37
A
132219
D
Common Stock
2023-04-17
4
S
0
112219
9.5397
D
20000
D
Employee Stock Option (right to buy)
4.37
2023-04-13
4
M
0
7781
0
D
2031-05-16
Common Stock
7781
282119
D
Employee Stock Option (right to buy)
4.37
2023-04-17
4
M
0
112219
0
D
2031-05-16
Common Stock
112219
169900
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $8.985, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.80, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter.
/s/ Paul Quinlan, as attorney-in-fact for Dennis D. Kim
2023-04-17